Equities Analysts Set Expectations for UTHR Q2 Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for United Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will earn $6.99 per share for the quarter, down from their prior estimate of $7.31. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.94 EPS, Q4 2025 earnings at $8.32 EPS, FY2025 earnings at $29.43 EPS and FY2028 earnings at $32.33 EPS.

A number of other research firms also recently issued reports on UTHR. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group raised their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Trading Down 0.5 %

UTHR opened at $308.59 on Monday. The stock has a fifty day simple moving average of $357.53 and a two-hundred day simple moving average of $360.79. The company has a market cap of $13.86 billion, a price-to-earnings ratio of 13.55, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the prior year, the company earned $4.36 earnings per share.

Institutional Trading of United Therapeutics

A number of large investors have recently made changes to their positions in the business. Wealthfront Advisers LLC grew its holdings in United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. boosted its position in United Therapeutics by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock valued at $1,567,253,000 after buying an additional 32,213 shares during the period. FMR LLC boosted its position in United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock valued at $519,170,000 after buying an additional 393,777 shares during the period. Geode Capital Management LLC boosted its position in United Therapeutics by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company’s stock valued at $401,184,000 after buying an additional 44,277 shares during the period. Finally, AQR Capital Management LLC boosted its position in United Therapeutics by 0.8% in the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company’s stock valued at $344,176,000 after buying an additional 7,710 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the sale, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 124,164 shares of company stock worth $45,278,893. 11.90% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.